Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAF<sup>V600E</sup> Mutant A375 Melanoma Cells
The eIF4F complex inhibitor reactivates ERK1/2-EZH2 and AKT1 signaling pathways, resulting in resistance to both eIF4Fi and VEM. Combined administration of an eIF4Fi with EZH2 and AKT1 inhibitors effectively enhances sensitivity to both eIF4F complex and BRAF inhibitors.
Authors
- Sae Hwi Ki (ORCID: https://orcid.org/0000-0001-9194-9681)
- Yuanxin Miao
- Fengyun Hao
Institutions
- Qingdao University (CN)
- Inha University (KR)
- Affiliated Hospital of Qingdao University (CN)
- Inha University Hospital (KR)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2026-01-01
- DOI
- https://doi.org/10.32604/or.2025.071034
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00